N
ACOR

Natixis’s Acorda Therapeutics ACOR Stock Holding History

Natixis’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-107
Closed -$303K – 1248
2017
Q3 		$303K Buy
+107
New +$282K ﹤0.01% 902

Other funds holding ACOR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Natixis's ACOR Position: Q4 2017 in Review

Natixis sold out of Acorda Therapeutics (ACOR) in Q4 2017, closing a stake of 107 shares — an estimated $303K sold.

Natixis first reported a position in ACOR in Q3 2017 and held it in 1 quarter. The position peaked at $303K in Q3 2017. 150 funds tracked by Wall St. Rank hold ACOR as of Q4 2017.

  • Natixis reported no remaining Acorda Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Natixis sold 107 Acorda Therapeutics shares in Q4 2017, an estimated $303K.
  • Natixis first reported a position in Acorda Therapeutics in Q3 2017 and held it in 1 quarter.
  • Natixis's Acorda Therapeutics position peaked at $303K in Q3 2017.
  • 150 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2017.

Based on Natixis's 13F filing for Q4 2017, filed 14 Feb 2018.